サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1792391

糖尿病網膜症の市場レポート：タイプ別、治療タイプ別、エンドユーザー別、地域別、2025年～2033年

Diabetic Retinopathy Market Report by Type, Treatment Type, End-User (Hospitals and Pharmacies, Eye Clinics, Ambulatory Surgical Centres, and Others), and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 138 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
糖尿病網膜症の市場レポート：タイプ別、治療タイプ別、エンドユーザー別、地域別、2025年～2033年
出版日: 2025年08月01日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の糖尿病網膜症市場規模は2024年に85億米ドルに達しました。今後、IMARC Groupは、2033年には132億米ドルに達し、2025年から2033年にかけて5％の成長率（CAGR）を示すと予測しています。糖尿病有病率の急増、効果的な治療に対する需要の高まり、糖尿病網膜症の早期診断と治療に関する意識の高まりが、市場を牽引する主な要因の一つです。

糖尿病網膜症（DR）は、光を感知して脳に信号を送る目の部分である網膜に影響を及ぼす糖尿病の一般的な合併症です。高血糖が網膜の細い血管にダメージを与え、血管が漏れたり詰まったりすることで発症します。放置すると視力低下や失明につながります。糖尿病網膜症には大きく分けて、非増殖性糖尿病網膜症と増殖性糖尿病網膜症の2種類があります。その診断には、フルオレセイン血管造影や光干渉断層計などの検査を含む総合的な眼科検査が必要です。これらの検査は、DRの存在と重症度を特定するのに役立ち、早期の介入と治療を可能にします。現在、DRにはステロイド眼内注射、レーザー治療、硝子体手術などの治療法があります。眼内ステロイド注射は眼球の炎症や腫れを抑えるのに役立ち、レーザー治療は漏れた血管を塞いで網膜のさらなる損傷を防ぐのに使われます。さらに重症の場合は、眼球から血液や瘢痕組織を取り除くために硝子体手術が必要になることもあります。

糖尿病網膜症の市場動向：

世界の糖尿病網膜症市場は、主に糖尿病の有病率の上昇と老年人口の増加により、大きな成長を遂げています。これに伴い、主要企業は糖尿病網膜症の新たな治療ソリューションの開発に積極的に取り組んでおり、市場の成長を後押ししています。これとは別に、抗VEGF薬や徐放性インプラントなどの新薬や治療法の開発も市場成長に大きく貢献しています。さらに、糖尿病網膜症の診断や治療における遠隔医療や人工知能（AI）の採用が拡大していることも、市場の成長を後押ししています。糖尿病網膜症とその潜在的な影響に対する認識の高まりによる効果的な治療に対する需要の高まりは、もう一つの成長促進要因として作用しています。さらに、糖尿病網膜症の早期診断と治療に関する意識の高まりと眼科技術の進歩が、市場の成長を促進しています。その他の要因としては、ヘルスケア支出の増加、眼科医療サービス向上のための様々な政府イニシアチブの実施、有利な償還政策の利用可能性などが市場成長を促進しています。

本レポートで扱う主な質問

  • 糖尿病網膜症の世界市場はこれまでどのように推移してきたのか？
  • 世界の糖尿病網膜症市場における市場促進要因、市場抑制要因、市場機会は何か？
  • 糖尿病網膜症の世界市場において、それぞれの促進要因、抑制要因、機会が与える影響とは？
  • 主要な地域市場とは？
  • 最も魅力的な糖尿病網膜症市場はどの国か？
  • タイプ別の市場内訳は？
  • 糖尿病網膜症市場で最も魅力的なタイプは？
  • 治療タイプ別の市場内訳は？
  • 糖尿病網膜症市場で最も魅力的な治療タイプは？
  • エンドユーザー別の市場内訳は？
  • 糖尿病網膜症市場で最も魅力的なエンドユーザーは？
  • 糖尿病網膜症世界市場の競合構造は？
  • 糖尿病網膜症の世界市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の糖尿病網膜症市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 増殖性糖尿病網膜症
  • 非増殖性網膜症

第7章 市場内訳：治療タイプ別

  • 抗VEGF薬
  • ステロイドインプラント
  • レーザー手術
  • 硝子体切除術

第8章 市場内訳：エンドユーザー別

  • 病院と薬局
  • 眼科クリニック
  • 外来手術センター（ASC）
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Alimera Sciences
    • Allergan Plc
    • Ampio Pharmaceuticals
    • Bayer Healthcare
    • BCN Peptides
    • Genentech
    • Kowa Group
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Sirnaomics Inc.
図表

List of Figures

  • Figure 1: Global: Diabetic Retinopathy Market: Major Drivers and Challenges
  • Figure 2: Global: Diabetic Retinopathy Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Diabetic Retinopathy Market: Breakup by Type (in %), 2024
  • Figure 4: Global: Diabetic Retinopathy Market: Breakup by Treatment Type (in %), 2024
  • Figure 5: Global: Diabetic Retinopathy Market: Breakup by End-User (in %), 2024
  • Figure 6: Global: Diabetic Retinopathy Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Diabetic Retinopathy Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 8: Global: Diabetic Retinopathy (Proliferative Diabetic Retinopathy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Diabetic Retinopathy (Proliferative Diabetic Retinopathy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Diabetic Retinopathy (Non-proliferative Retinopathy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Diabetic Retinopathy (Non-proliferative Retinopathy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Diabetic Retinopathy (Anti VEGF Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Diabetic Retinopathy (Anti VEGF Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Diabetic Retinopathy (Steroid Implants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Diabetic Retinopathy (Steroid Implants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Diabetic Retinopathy (Laser Surgeries) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Diabetic Retinopathy (Laser Surgeries) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Diabetic Retinopathy (Vitrectomy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Diabetic Retinopathy (Vitrectomy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Diabetic Retinopathy (Hospitals and Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Diabetic Retinopathy (Hospitals and Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Diabetic Retinopathy (Eye Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Diabetic Retinopathy (Eye Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Diabetic Retinopathy (Ambulatory Surgical Centres-ASCs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Diabetic Retinopathy (Ambulatory Surgical Centres-ASCs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Diabetic Retinopathy (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Diabetic Retinopathy (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia Pacific: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia Pacific: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Diabetic Retinopathy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Diabetic Retinopathy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Global: Diabetic Retinopathy Industry: SWOT Analysis
  • Figure 77: Global: Diabetic Retinopathy Industry: Value Chain Analysis
  • Figure 78: Global: Diabetic Retinopathy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Diabetic Retinopathy Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Diabetic Retinopathy Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Diabetic Retinopathy Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 4: Global: Diabetic Retinopathy Market Forecast: Breakup by End-User (in Million USD), 2025-2033
  • Table 5: Global: Diabetic Retinopathy Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Diabetic Retinopathy Market: Competitive Structure
  • Table 7: Global: Diabetic Retinopathy Market: Key Players
目次
Product Code: SR112025A1932

The global diabetic retinopathy market size reached USD 8.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 13.2 Billion by 2033, exhibiting a growth rate (CAGR) of 5% during 2025-2033. The surging prevalence of diabetes, rising demand for effective treatments, and growing awareness regarding early diagnosis and treatment of diabetic retinopathy represent some of the key factors driving the market.

Diabetic retinopathy (DR) is a common complication of diabetes that affects the retina, the part of the eye that senses light and sends signals to the brain. It occurs when high blood sugar levels damage the small blood vessels in the retina, causing them to leak or become blocked. This can lead to vision loss or blindness if left untreated. There are two main types of diabetic retinopathy, namely non-proliferative diabetic retinopathy and proliferative diabetic retinopathy. Its diagnosis involves a comprehensive eye exam, which may include tests such as fluorescein angiography and optical coherence tomography. These tests can help to identify the presence and severity of DR, allowing for early intervention and treatment. Currently, there are several treatment options available for DR, including the use of intraocular steroid injections, laser treatment, and vitrectomy. Intraocular steroid injections can help to reduce inflammation and swelling in the eye, while laser treatment can be used to seal leaking blood vessels and prevent further damage to the retina. In more severe cases, a vitrectomy may be necessary to remove blood or scar tissue from the eye.

Diabetic Retinopathy Market Trends:

The global diabetic retinopathy market is witnessing significant growth, primarily driven by the rising prevalence of diabetes and the increasing geriatric population. In line with this, key players are actively working to develop new therapeutic solutions for diabetic retinopathy, which is bolstering market growth. Apart from this, the development of new drugs and therapies, such as anti-VEGF agents and sustained-release implants, has also significantly contributed to market growth. Additionally, the escalating adoption of telemedicine and artificial intelligence (AI) in the diagnosis and treatment of diabetic retinopathy is driving the market growth. The rising demand for effective treatments due to the growing awareness of diabetic retinopathy and its potential consequences is acting as another growth-inducing factor. Furthermore, the surging awareness regarding early diagnosis and treatment of diabetic retinopathy, coupled with advancements in ophthalmic technology, are fueling the market growth. Other factors, such as increasing healthcare expenditure, the implementation of various government initiatives to improve eye care services, and the availability of favorable reimbursement policies, are propelling the market growth.

Key Market Segmentation:

Type Insights:

  • Proliferative Diabetic Retinopathy
  • Non-proliferative Retinopathy

Treatment Type Insights:

  • Anti VEGF Drugs
  • Steroid Implants
  • Laser Surgeries
  • Vitrectomy

End-User Insights:

  • Hospitals and Pharmacies
  • Eye Clinics
  • Ambulatory Surgical Centres (ASCs)
  • Others

Regional Insights:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. As per the report, North America dominates the market. Some of the factors accelerating the North America diabetic retinopathy market include the increasing prevalence of diabetes, growing awareness about diabetic retinopathy, and advancements in diagnostic and treatment technologies.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global diabetic retinopathy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alimera Sciences, Allergan PLC, Ampio Pharmaceuticals, Bayer Healthcare, BCN Peptides, Genentech, Kowa Group, Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global diabetic retinopathy market performed so far, and how will it perform in the coming years ?
  • What are the drivers, restraints, and opportunities in the global diabetic retinopathy market ?
  • What is the impact of each driver, restraint, and opportunity on the global diabetic retinopathy market ?
  • What are the key regional markets ?
  • Which countries represent the most attractive diabetic retinopathy market ?
  • What is the breakup of the market based on the type ?
  • Which is the most attractive type in the diabetic retinopathy market ?
  • What is the breakup of the market based on the treatment type ?
  • Which is the most attractive treatment type in the diabetic retinopathy market ?
  • What is the breakup of the market based on the end-user ?
  • Which is the most attractive end-user in the diabetic retinopathy market ?
  • What is the competitive structure of the global diabetic retinopathy market ?
  • Who are the key players/companies in the global diabetic retinopathy market ?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Diabetic Retinopathy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Proliferative Diabetic Retinopathy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Non-proliferative Retinopathy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Treatment Type

  • 7.1 Anti VEGF Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Steroid Implants
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Laser Surgeries
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Vitrectomy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End-User

  • 8.1 Hospitals and Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Eye Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgical Centres (ASCs)
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Alimera Sciences
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
    • 13.3.2 Allergan Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Ampio Pharmaceuticals
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Bayer Healthcare
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 BCN Peptides
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 Genentech
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 SWOT Analysis
    • 13.3.7 Kowa Group
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 Novartis AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 Regeneron Pharmaceuticals Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Sirnaomics Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio